Skip to main content
Premium Trial:

Request an Annual Quote

Singulex Collaborating with Novartis, Opening European Facility

NEW YORK (GenomeWeb News) – Alameda, Calif.-based Singulex announced yesterday that it is collaborating with the Swiss pharmaceutical company Novartis and that it has opened a new facility in Paris to serve European collaborators.
 
Under the agreement, a Novartis facility in Basel, Switzerland, has acquired Singulex’s Erenna system, which is used for detecting changes in protein biomarkers in samples from several species. In addition, Singulex plans to help Novartis create biomarker assays related to the pharmaceutical company’s drug development programs.
 
Terms of the collaboration were not disclosed.
 
Meanwhile, the Singulex center in France is intended to bring Singulex’s biomarker diagnostic systems and immunoassay technology, including Erenna, closer to its European partners.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.